Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. Soc. Bras. Med. Trop ; 54: e05362020, 2021. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1155593

RESUMEN

Abstract INTRODUCTION: Artemisinin-based combination therapy (ACT), such as artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine (DP), and artemether-lumefantrine (AL), is the first-line treatment for malaria in many malaria-endemic areas. However, we lack a detailed evaluation of the cardiotoxicity of these ACTs. This study aimed to analyze the electrocardiographic effects of these three ACTs in malaria patients. METHODS: We analyzed the clinical data of 89 hospitalized patients with falciparum malaria who had received oral doses of three different ACTs. According to the ACTs administered, these patients were divided into three treatment groups: 27 treated with AP (Artequick), 31 with DP (Artekin), and 31 with AL (Coartem). Electrocardiograms and other indicators were recorded before and after the treatment. The QT interval was calculated using Fridericia's formula (QTcF) and Bazett's formula (QTcB). RESULTS: Both QTcF and QTcB interval prolongation occurred in all three groups. The incidence of such prolongation between the three groups was not significantly different. The incidence of both moderate and severe prolongation was not significantly different between the three groups. The ΔQTcF and ΔQTcB of the three groups were not significantly different. The intra-group comparison showed significant prolongation of QTcF after AL treatment. CONCLUSIONS: Clinically recommended doses of DP, AL, and AP may cause QT prolongation in some malaria patients but do not cause torsades de pointes ventricular tachycardia or other arrhythmias.


Asunto(s)
Humanos , Malaria Falciparum/tratamiento farmacológico , Artemisininas/efectos adversos , Malaria/tratamiento farmacológico , Antimaláricos/efectos adversos , Quinolinas , Combinación de Medicamentos , Electrocardiografía , Arteméter/uso terapéutico , Combinación Arteméter y Lumefantrina/uso terapéutico
2.
Rev. Soc. Bras. Med. Trop ; 52: e20180453, 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1041531

RESUMEN

Abstract INTRODUCTION: Concern regarding the cardiotoxicity of antimalarials has been renewed because of their potential to cause QT/QTc interval prolongation related to torsade de pointes (TdP). Artemisinin-piperaquine (AP) is considered an effective artemisinin-based combination therapy (ACT) for malaria. METHODS: This study involved a retrospective analysis of clinical data of 93 hospitalized malaria patients who had received AP orally. Electrocardiograms (ECGs) were obtained at specific time points in the original study. RESULTS: Some cases of QT prolongation were observed. However, no TdP was found. CONCLUSIONS: AP may cause QT interval prolongation in some malaria patients but may not lead to TdP.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Quinolinas/efectos adversos , Síndrome de QT Prolongado/inducido químicamente , Malaria Falciparum/tratamiento farmacológico , Artemisininas/efectos adversos , Antimaláricos/efectos adversos , Quinolinas/uso terapéutico , Síndrome de QT Prolongado/diagnóstico , Estudios Retrospectivos , Artemisininas/uso terapéutico , Quimioterapia Combinada , Electrocardiografía , Persona de Mediana Edad , Antimaláricos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA